Eravacycline Medicine 03 June 2025 Extended indication Eravacycline monotherapy for treatment of Complicated intra-abdominal infection in children and adolescents. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Eravacycline Domain Infectious diseases Reason of inclusion Indication extension IND Main indication Bacterial infections Extended indication Eravacycline monotherapy for treatment of Complicated intra-abdominal infection in children and adolescents. Current proprietary name Already available biosimilars / generics Proprietary name Xerava Manufacturer PAION Portfolio holder Mechanism of action Antibiotic Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Is nauw gerelateerd aan tigecycline en tetracyclines met werkzaamheid tegen meticilline resistente Staphylococcus aureus (MRSA) en carbapenem resistente enterobacteriaceae. Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP No Submission date April 2025 Expected Registration February 2026 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References NCT06794541 Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks